Advances in the management of high-risk localised and metastatic prostate cancer

BJU International

Volumn 109, Issue SUPPL. 2, 2012, Pages 8-13

  Bellmunt, Joaquim ^a   Attard, Gerhardt ^b   Bahl, Amit ^c   Huland, Hartwig ^d   Klotz, Laurence ^e   Kuban, Deborah ^f   Oudard, Stéphane ^g   Watson, William ^h  

^a HOSPITAL DEL MAR   (Spain)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

abiraterone acetate; androgen deprivation therapy; androgen receptor; cabazitaxel; chemotherapy; radiation therapy

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; AFLIBERCEPT; ANDROGEN RECEPTOR LIGAND; CABAZITAXEL; CLUSTERIN; CUSTIRSEN; DOCETAXEL; GONADORELIN AGONIST; HEMOGLOBIN A1C; IPILIMUMAB; LIGAND; LIPID; MITOXANTRONE; ORTERONEL; PACLITAXEL; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; TESTOSTERONE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; BLOOD PRESSURE; BODY FAT; BODY WEIGHT; BONE DENSITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; GLEASON SCORE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IN VIVO STUDY; INSULIN SENSITIVITY; INTESTINE FUNCTION; LIPID BLOOD LEVEL; LONG TERM CARE; METASTASIS POTENTIAL; MONOTHERAPY; NEUTROPENIA; NOMOGRAM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE; RISK REDUCTION; SEXUAL FUNCTION; SURVIVAL RATE; URETHRA FUNCTION; URINE INCONTINENCE;

ANDROGEN RECEPTOR ANTAGONISTS; ANDROSTADIENES; CARDIOVASCULAR DISEASES; CHEMOTHERAPY, ADJUVANT; CONGRESSES AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TAXOIDS;

EID: 84856208003     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10871.x     Document Type: Conference Paper

References (67)

1. Porter CR, Kodama K, Gibbons RP, et al,. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 2006; 176: 569-74 (Pubitemid 43927880)
2. Yossepowitch O, Eggener SE, Bianco FJ Jr, et al,. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007; 178: 493-9 (Pubitemid 47030486)
3. Fitzsimons NJ, Presti JC Jr, Kane CJ, et al,. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? J Urol 2006; 176: 2453-8 (Pubitemid 44755068)
4. Donohue JF, Bianco FJ Jr, Kuroiwa K, et al,. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol 2006; 176: 991-5 (Pubitemid 44142600)
5. Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC,. Radical prostatectomy for clinical stage T3a disease. Cancer 2007; 109: 1273-8 (Pubitemid 46466553)
6. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H,. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007; 51: 121-8
7. Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA,. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006; 176: 564-8 (Pubitemid 43927886)
8. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT,. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528-34 (Pubitemid 34074521)
9. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW,. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 2006; 176: 1404-8 (Pubitemid 44307204)
10. Bianco FJ Jr, Scardino PT, Eastham JA,. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ('trifecta'). Urology 2005; 66: 83-94 (Pubitemid 41356564)
11. Zelefsky MJ, Eastham JA, Cronin AM, et al,. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010; 28: 1508-13
12. Steuber T, Budaus L, Walz J, et al,. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int 2011; 107: 1755-61
13. Kuban DA, Levy LB, Cheung MR, et al,. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 2011; 79: 1310-7
14. Kuban DA, Tucker SL, Dong L, et al,. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 67-74 (Pubitemid 350251041)
15. Bolla M, Van Tienhoven G, Warde P, et al,. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066-73
16. Boorjian SA, Karnes RJ, Viterbo R, et al,. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011; 117: 2883-91
17. Sanda MG, Dunn RL, Michalski J, et al,. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250-61 (Pubitemid 351439226)
18. Tannock IF, de Wit R, Berry WR, et al,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12 (Pubitemid 39315317)
19. de Bono JS, Oudard S, Ozguroglu M, et al,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54
20. Oh WK,. The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer. J Urol 2003; 170: S28-32
21. Flaig TW, Tangen CM, Hussain MH, et al,. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008; 26: 1532-6
22. Smith MR, Kabbinavar F, Saad F, et al,. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 2918-25 (Pubitemid 46224110)
23. Saylor PJ, Smith MR,. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009; 181: 1998-2006
24. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-56 (Pubitemid 46630983)
25. Smith MR, Lee H, Nathan DM,. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-8
26. Smith MR, Finkelstein JS, McGovern FJ, et al,. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603 (Pubitemid 34158224)
27. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-64 (Pubitemid 40096612)
28. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM,. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002; 87: 3656-61 (Pubitemid 34879508)
29. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI,. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005-7
30. Denmeade SR, Lin XS, Isaacs JT,. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28: 251-65 (Pubitemid 26119117)
31. Morrissey C, Buser A, Scolaro J, O'Sullivan J, Moquin A, Tenniswood M,. Changes in hormone sensitivity in the ventral prostate of aging Sprague-Dawley rats. J Androl 2002; 23: 341-51 (Pubitemid 34297323)
32. Pienta KJ, Bradley D,. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1665-71
33. Attard G, Cooper CS, de Bono JS,. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009; 16: 458-62
34. Maitland NJ, Collins AT,. Cancer stem cells-a therapeutic target? Curr Opin Mol Ther 2010; 12: 662-73
35. Bellmunt J, Oh WK,. Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol 2010; 2: 189-207
36. Scher HI, Beer TM, Higano CS, et al,. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46
37. Tran C, Ouk S, Clegg NJ, et al,. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90
38. Attard G, Belldegrun AS, de Bono JS,. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 2005; 96: 1241-6 (Pubitemid 41743917)
39. Chi KN, Hotte SJ, Yu EY, et al,. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 4247-54
40. Sternberg CN, Dumez H, Van Poppel H, et al,. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20: 1264-9
41. Halabi S, Small EJ, Kantoff PW, et al,. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-7 (Pubitemid 46606398)
42. Smaletz O, Scher HI, Small EJ, et al,. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972-82
43. Svatek R, Karakiewicz PI, Shulman M, Karam J, Perrotte P, Benaim E,. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer. Eur Urol 2006; 49: 666-74 (Pubitemid 43374728)
44. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M,. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2010; 16: 203-11
45. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M,. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396-403 (Pubitemid 350075029)
46. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S,. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010; 46: 517-25
47. Mottet N, Bellmunt J, Bolla M, et al,. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-83
48. Bellmunt J, Rosenberg JE, Choueiri TK,. Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol 2009; 56: 606-8
49. Attard G, Richards J, de Bono JS,. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011; 17: 1649-57
50. Sonpavde G, Attard G, Bellmunt J, et al,. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol 2011; 60: 270-8
51. Attard G, Reid AH, A'Hern R, et al,. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-8
52. Attard G, Reid AH, Yap TA, et al,. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-71
53. Danila DC, Morris MJ, de Bono JS, et al,. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-501
54. Reid AH, Attard G, Danila DC, et al,. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-95
55. Ryan CJ, Smith MR, Fong L, et al,. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28: 1481-8
56. de Bono JS, Logothetis CJ, Molina A, et al,. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
57. Kantoff PW, Higano CS, Shore ND, et al,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22
58. Massard C, Fizazi K,. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 2011; 17: 3876-83
59. Fong L, Kwek SS, O'Brien S, et al,. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69: 609-15
60. George D, Moul JW,. Emerging treatment options for patients with castration-resistant prostate cancer. Prostate 2011; doi: 10.1002/pros.21435. Epub ahead of print
61. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-5
62. Bissery M, Bouchard H, Riou J, et al,. Preclinical evaluation of TXD258, a new taxoid. Proc Am Assoc Cancer Res 2000; 41: 214, Abstract 1364
63. Vrignaud P, Lejeune P, Bissery M,. TXD258, a new taxoid with oral antitumor activity. Proc Am Assoc Cancer Res 2000; 41: 214, Abstract 1975
64. Villanueva C, Bazan F, Kim S, et al,. Cabazitaxel: a novel microtubule inhibitor. Drugs 2011; 71: 1251-8
65. Mita AC, Denis LJ, Rowinsky EK, et al,. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 723-30
66. Pivot X, Koralewski P, Hidalgo JL, et al,. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19: 1547-52
67. Villanueva C, Awada A, Campone M, et al,. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer 2011; 47: 1037-45